In the setting of AD, CAR-T cells can be programmed to specifically target Aβ or tau proteins, and CAR-T therapies have had significant success in cancer treatment, although their use in AD is still in the early stages of research. The gene discussed is MAPT; the disease is Alzheimer disease.